247 related articles for article (PubMed ID: 8402391)
1. Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV).
Yuen VG; Orvig C; Thompson KH; McNeill JH
Can J Physiol Pharmacol; 1993; 71(3-4):270-6. PubMed ID: 8402391
[TBL] [Abstract][Full Text] [Related]
2. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV).
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1993; 71(3-4):263-9. PubMed ID: 8402390
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
[TBL] [Abstract][Full Text] [Related]
4. Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats.
Yuen VG; Orvig C; McNeill JH
Am J Physiol; 1997 Jan; 272(1 Pt 1):E30-5. PubMed ID: 9038848
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo.
Marzban L; Rahimian R; Brownsey RW; McNeill JH
Endocrinology; 2002 Dec; 143(12):4636-45. PubMed ID: 12446591
[TBL] [Abstract][Full Text] [Related]
6. The influence of BMOV [bis(maltolato)oxovanadium(IV)] on biochemical and morphological alterations characteristic for streptozotocin-diabetic rat liver Golgi complexes.
Dabroś W; Dziga D; Kordowiak AM
Pol J Pathol; 2002; 53(4):205-13. PubMed ID: 12597338
[TBL] [Abstract][Full Text] [Related]
7. Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats.
Yuen VG; Vera E; Battell ML; Li WM; McNeill JH
Diabetes Res Clin Pract; 1999 Jan; 43(1):9-19. PubMed ID: 10199584
[TBL] [Abstract][Full Text] [Related]
8. Bis(maltolato)oxovanadium(IV) (BMOV) Attenuates Apoptosis in High Glucose-Treated Cardiac Cells and Diabetic Rat Hearts by Regulating the Unfolded Protein Responses (UPRs).
Cong XQ; Piao MH; Li Y; Xie L; Liu Y
Biol Trace Elem Res; 2016 Oct; 173(2):390-8. PubMed ID: 26983714
[TBL] [Abstract][Full Text] [Related]
9. Effect of chronic treatment with Bis(maltolato)oxovanadium (IV) in rat model of non-insulin-dependent-diabetes.
Shinde UA; Mehta AA; Goyal RK
Indian J Exp Biol; 2001 Sep; 39(9):864-70. PubMed ID: 11831366
[TBL] [Abstract][Full Text] [Related]
10. Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats.
Reul BA; Amin SS; Buchet JP; Ongemba LN; Crans DC; Brichard SM
Br J Pharmacol; 1999 Jan; 126(2):467-77. PubMed ID: 10077240
[TBL] [Abstract][Full Text] [Related]
11. Effects of bis(maltolato) oxovanadium (IV) on protein serine kinases in skeletal muscle of streptozotocin-diabetic rats.
Bhanot S; Girn J; Poucheret P; McNeill JH
Mol Cell Biochem; 1999 Dec; 202(1-2):131-40. PubMed ID: 10706003
[TBL] [Abstract][Full Text] [Related]
12. A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.
Winter CL; Lange JS; Davis MG; Gerwe GS; Downs TR; Peters KG; Kasibhatla B
Exp Biol Med (Maywood); 2005 Mar; 230(3):207-16. PubMed ID: 15734724
[TBL] [Abstract][Full Text] [Related]
13. Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds.
Wasan KM; Risovic V; Yuen VG; McNeill JH
J Trace Elem Med Biol; 2006; 19(4):251-8. PubMed ID: 16443173
[TBL] [Abstract][Full Text] [Related]
14. The effects of vanadium treatment on bone in diabetic and non-diabetic rats.
Facchini DM; Yuen VG; Battell ML; McNeill JH; Grynpas MD
Bone; 2006 Mar; 38(3):368-77. PubMed ID: 16256449
[TBL] [Abstract][Full Text] [Related]
15. Streptozotocin-induced alterations in rat liver Golgi complexes are ameliorated by BMOV [Bis(maltolato)oxovanadium(IV)] activity.
Kordowiak AM; Dziga D; Dabroś W
Horm Metab Res; 2004 Mar; 36(3):148-54. PubMed ID: 15057667
[TBL] [Abstract][Full Text] [Related]
16. Bis(maltolato)oxovanadium(IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats.
Bhanot S; Bryer-Ash M; Cheung A; McNeill JH
Diabetes; 1994 Jul; 43(7):857-61. PubMed ID: 8013747
[TBL] [Abstract][Full Text] [Related]
17. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes.
Thompson KH; Chiles J; Yuen VG; Tse J; McNeill JH; Orvig C
J Inorg Biochem; 2004 May; 98(5):683-90. PubMed ID: 15134913
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of vanadium in diabetic rats are independent of changes in PI-3 kinase activity in skeletal muscle.
Mohammad A; Bhanot S; McNeill JH
Mol Cell Biochem; 2001 Jul; 223(1-2):103-8. PubMed ID: 11681710
[TBL] [Abstract][Full Text] [Related]
19. In vivo effects of insulin and bis(maltolato)oxovanadium (IV) on PKB activity in the skeletal muscle and liver of diabetic rats.
Marzban L; Bhanot S; McNeill JH
Mol Cell Biochem; 2001 Jul; 223(1-2):147-57. PubMed ID: 11681716
[TBL] [Abstract][Full Text] [Related]
20. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Zhang SQ; Zhong XY; Chen GH; Lu WL; Zhang Q
J Pharm Pharmacol; 2008 Jan; 60(1):99-105. PubMed ID: 18088510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]